TITLE

Lonza to Build Second Plant in Singapore for $350 Million

AUTHOR(S)
Scott, Alex
PUB. DATE
December 2006
SOURCE
Chemical Week;12/13/2006, Vol. 168 Issue 41, p29
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
the article reports that Lonza has signed a deal with biotechnology investment company BioOne Capital to create a joint venture, Lonza Biologics Tuas, that will invest $350 million to build a mammalian cell culture biologic drug manufacturing plant in Singapore. Lonza Biologics Tuas will produce biologic drugs at commercial scale using mammalian cell technology.
ACCESSION #
23577261

 

Related Articles

  • Lonza Plans Biomanufacturing JV in Singapore.  // Chemical Week;8/24/2005, Vol. 167 Issue 28, p41 

    Reports on the joint venture of Lonza and bioscience fund management company BioOne Capital in manufacturing biopharmaceuticals in Singapore. Description of the planned biopharmaceutical plant; Target completion date of the joint venture project.

  • NEW PROJECTS. Gordon, Michael // European Chemical News;8/22/2005, Vol. 83 Issue 2160, p16 

    Presents news briefs on projects of chemical companies as of August 22, 2005. Success of Aker Kavaerner to win a plant expansion contract from Saudi European Petrochemical Co. in Saudi Arabia; Decision of Huntsman to increase its ethylene carbonate manufacturing capacity at a plant in Texas;...

  • New diagnostic j-v in Singapore.  // Medical Device Daily;12/13/2007, Vol. 11 Issue 226, p8 

    The article reports on the joint venture formed by Qiagen and Bio*One Capital to establish Dx Assays in Singapore. Qiagen chief executive Peer Schatz said the in-depth expertise and talent pool in biomedical research makes Singapore an ideal location for a centre for assay development. He added...

  • Asian advanced mammalian cell culture plant.  // Pharmaceutical Technology Europe;Apr2006, Vol. 18 Issue 4, p19 

    The article reports on the joint venture agreement between Lonza and BioOne to construct a large-scale mammalian cell culture manufacturing facility in the Tuas Biomedical Park in Singapore. The plant will manufacture commercial biophamaceuticals. The total investment for the plant is $250 million.

  • Biopharma first for Lonza. Lazell, Mark; Gordon, Michael // ICIS Chemical Business;2/20/2006, Vol. 1 Issue 7, p26 

    The article reports on the construction of a biopharmaceuticals manufacturing facility in Singapore under a joint venture agreement signed between Swiss group Lonza and Singapore investment company BioOne Capital. The project will extend the biopharmaceutical business of Lonza. According to...

  • Lonza Advances Manufacturing Strategy. Van Arnum, Patricia // Pharmaceutical Technology;Feb2007, Vol. 31 Issue 2, p24 

    The article reports on the joint venture called the Lonza Biologics Tuacs, from the collaboration of Lonza Group Ltd. and BioOne Capital, which aims at the construction of a large-scale mammalian cell-culture facility worth $350 million in Singapore. The facility will consist of four mammalian...

  • International Scene.  // Chemical Business;Mar2006, Vol. 20 Issue 3, p77 

    Presents news briefs related to the global chemical industry, as of March 2006. Publication of a guide to compact double-block-and-bleed manifolds for connecting process instrumentation by Parker Instrumentation; Overview of a joint venture between Lonza Group Ltd. and BioOne Capital in...

  • Project Proposals Evaluation. Encheva, Sylvia; Tumin, Sharil // AIP Conference Proceedings;8/13/2009, Vol. 1148 Issue 1, p884 

    Collaboration among various firms has been traditionally used trough single project joint ventures for bonding purposes. Eventhough the performed work is usually beneficial to some extend to all participants, the type of collaboration option to be adapted is strongly influenced by overall...

  • Lonza to go big in biopharma. Lazell, Mark // Chemical Market Reporter;2/20/2006, Vol. 269 Issue 7, p4 

    The article reports on the corporate expansion of Lonza and Singapore partner BioOne Capital on their new biopharmaceutical facility. The facility was forecast to meet growing global demand for commercial mammalian. As the first commercial-scale facility, the plant will include up to four...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics